高级检索

    不同危险分层量表在肺动脉高压患者中的临床应用对比

    Comparison of clinical application of different risk stratification scales in patients with pulmonary hypertension

    • 摘要: 目的 对《中国肺高血压诊断和治疗指南2018》和《中国肺动脉高压诊断和治疗指南(2021版)》推荐的两个成人肺动脉高压危险分层量表在真实世界中的临床应用进行比较。方法 收集2016年1月—2021年2月于徐州医科大学附属医院和重庆医科大学附属第一医院就诊的127例肺动脉高压患者的临床资料,利用上述两个指南推荐的危险分层量表分别对患者进行危险分层和预后比较。结果 127例患者中男性21例(16.5%),女性106例(83.5%),中位年龄38.0(27.5,51.0)岁。将不同危险分层量表评估的低、中、高危患者进行同一分层级别的两两对比,WHO心功能分级、超声心动图指标、脑钠肽、血流动力学指标等的差异均无统计学意义(P>0.05)。依据不同危险分层量表分组后病例数分布的差异无统计学意义(P>0.05)。随访截至2022年3月30日,中位随访时间为30.6个月。生存曲线显示,2018版低、中、高危组和2021版低、中、高危组1年生存率均与预测的死亡风险一致。依据2018版危险分层量表,低、中、高危组5年生存率的差异无统计学意义(P>0.05);依据2021版危险分层量表,低、中、高危组5年生存率的差异有统计学意义(P<0.05)。结论 2018版和2021版危险分层量表对肺动脉高压患者1年死亡率的预测价值具有一致性;依据2021版危险分层量表得出的低、中、高危患者5年生存曲线与危险分层的预测结果一致。

       

      Abstract: Objective The clinical application of two adult pulmonary hypertension risk stratification scales recommended by Chinese Guidelines for Diagnosis and Treatment of Pulmonary Hypertension (2018 and 2021 Editions) in the real world. Methods Clinical data were collected from 127 pulmonary arterial hypertension patients who were admitted in the Affiliated Hospital of Xuzhou Medical University and the First Affiliated Hospital of Chongqing Medical University from January 2016 to February 2021. The risk stratification and prognosis of the patients were compared using the risk stratification scales recommended by the two guidelines mentioned above. Results A total of 127 patients were enrolled, including 21 men (16.5%) and 106 women (83.5%), with a median age of 38.0 (27.5, 51.0) years. There was no statistical difference in WHO cardiac function classification, echocardiographic indexes, brain natriuretic peptide, and hemodynamic indexes among the low, middle, and high risk groups of 2018 and 2021 Editions. There was no difference in the distribution of the number of cases according to different risk stratification scales. The follow-up period was until March 30, 2022, and the median follow-up time was 30.6 months. The survival curve showed that the 1-year survival rates of the low, medium, and high risk groups in both 2018 and 2021 Editions were consistent with the predicted risk of death. According to the risk stratification scale (2018 Edition), there was no statistical difference in 5-year survival rate among the low, medium, and high risk groups (P>0.05). According to the risk stratification scale (2021 Edition), statistical difference was found in 5-year survival rate among the low, middle and high risk groups (P<0.05). Conclusions The predictive value of the risk stratification scales (2018 and 2021 Editions) for 1-year mortality in patients with pulmonary arterial hypertension was consistent. According to the risk stratification scale (2021 Edition), The 5-year survival curves of the low, medium and high risk patients were consistent with the predicted results of risk stratification.

       

    /

    返回文章
    返回